ES2423193T3 - Protección antiviral con virus que contienen segmentos de genoma defectuoso - Google Patents

Protección antiviral con virus que contienen segmentos de genoma defectuoso Download PDF

Info

Publication number
ES2423193T3
ES2423193T3 ES09774920T ES09774920T ES2423193T3 ES 2423193 T3 ES2423193 T3 ES 2423193T3 ES 09774920 T ES09774920 T ES 09774920T ES 09774920 T ES09774920 T ES 09774920T ES 2423193 T3 ES2423193 T3 ES 2423193T3
Authority
ES
Spain
Prior art keywords
virus
influenza
mice
interferon
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09774920T
Other languages
English (en)
Spanish (es)
Inventor
Nigel Dimmock
Andrew Easton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Warwick
Original Assignee
University of Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Warwick filed Critical University of Warwick
Application granted granted Critical
Publication of ES2423193T3 publication Critical patent/ES2423193T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES09774920T 2008-12-12 2009-12-08 Protección antiviral con virus que contienen segmentos de genoma defectuoso Active ES2423193T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0822672 2008-12-12
GBGB0822672.2A GB0822672D0 (en) 2008-12-12 2008-12-12 Anti-viral protection with viruses containing a defective genome
PCT/GB2009/051666 WO2010067109A1 (en) 2008-12-12 2009-12-08 Anti-viral protection with viruses containing defective genome segments

Publications (1)

Publication Number Publication Date
ES2423193T3 true ES2423193T3 (es) 2013-09-18

Family

ID=40325992

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09774920T Active ES2423193T3 (es) 2008-12-12 2009-12-08 Protección antiviral con virus que contienen segmentos de genoma defectuoso

Country Status (11)

Country Link
US (1) US8691215B2 (enExample)
EP (1) EP2355834B1 (enExample)
CN (1) CN102256611B (enExample)
AU (1) AU2009326204B2 (enExample)
CA (1) CA2746495C (enExample)
DK (1) DK2355834T3 (enExample)
ES (1) ES2423193T3 (enExample)
GB (1) GB0822672D0 (enExample)
IN (1) IN2011KN02819A (enExample)
PL (1) PL2355834T3 (enExample)
WO (1) WO2010067109A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019685B1 (en) * 2006-05-24 2014-11-12 The University Of Warwick Defective interfering virus
GB2522615A (en) * 2014-01-16 2015-08-05 Univ Warwick Assay and medicament
WO2019206285A1 (en) * 2018-04-26 2019-10-31 The University Of Hong Kong Nucleic acid molecules and dual-functional peptides having antiviral activity and delivery activity, compositions and methods thereof
GB202209861D0 (en) * 2022-07-05 2022-08-17 Univ Court Univ St Andrews Viral vectors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
CN102302773B (zh) 2004-10-06 2014-05-14 米迪缪尼有限公司 冷藏温度稳定的流感疫苗组合物
JP4986859B2 (ja) 2004-11-11 2012-07-25 アボツト・バイオロジカルズ・ベー・ブイ 欠陥インフルエンザウイルス粒子
EP2019685B1 (en) 2006-05-24 2014-11-12 The University Of Warwick Defective interfering virus
GB2437799B (en) * 2006-05-24 2008-08-13 Univ Warwick Defective interfering virus

Also Published As

Publication number Publication date
DK2355834T3 (da) 2013-07-29
EP2355834B1 (en) 2013-05-01
IN2011KN02819A (enExample) 2015-07-10
CA2746495A1 (en) 2010-06-17
AU2009326204B2 (en) 2014-01-09
US8691215B2 (en) 2014-04-08
WO2010067109A1 (en) 2010-06-17
CN102256611A (zh) 2011-11-23
CN102256611B (zh) 2014-05-21
GB0822672D0 (en) 2009-01-21
CA2746495C (en) 2018-04-17
US20110243896A1 (en) 2011-10-06
AU2009326204A1 (en) 2011-06-23
PL2355834T3 (pl) 2014-03-31
EP2355834A1 (en) 2011-08-17

Similar Documents

Publication Publication Date Title
Easton et al. A novel broad-spectrum treatment for respiratory virus infections: influenza-based defective interfering virus provides protection against pneumovirus infection in vivo
Dimmock et al. Defective interfering influenza virus RNAs: time to reevaluate their clinical potential as broad-spectrum antivirals?
ES2655051T3 (es) Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
ES2286892T3 (es) Virus de influenza equina adaptados en frio.
Baker et al. Protection against lethal influenza with a viral mimic
JP6692835B2 (ja) 感染性疾患の予防及び／又は処置並びに腫瘍性疾患の処置のための弱毒化インフルエンザベクター
Cinatl Jr et al. The threat of avian influenza A (H5N1). Part I: epidemiologic concerns and virulence determinants
KR20090007599A (ko) 인플루엔자 바이러스 백신
ES2423193T3 (es) Protección antiviral con virus que contienen segmentos de genoma defectuoso
Pourhossein et al. Insights into the SARS-CoV2 outbreak; the great global challenge: A mini review
Suguitan Jr et al. The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus
US9089516B2 (en) Method of preventing or treating influenza A viral infection using cloned DI influenza A viral particles
CN101454023B (zh) 干扰缺损病毒
ES2913063T3 (es) Ensayo y medicamento
Patel et al. Pathogenesis of Ebola virus: A deadly virion hosted by bats
ES2401899B1 (es) Uso de una región no codificante del genoma del virus de la fiebre aftosa para la elaboración de un medicamento antiviral.
Kothavale et al. An Emerging Therapy for Dengue
Ramirez Carvajal Enhancement of Innate Immunity to Control Viral Infections in Livestock Species
Webster et al. Antiviral compounds for treatment of highly pathogenic avian influenza
Chauché Molecular evolution of equine influenza virus non-structural protein 1
Subbarao et al. The Immunology of Influenza Infection
Musick et al. Avian flu: The wrath of birdzilla or polly got the sniffles?
Ngunjiri Influenza virus noninfectious biologically active particle subpopulations: Detection, quantification, genetic complexity, function and their novel use as an in vitro screen for self-adjuvating live-attenuated influenza vaccines